FDA Warns Against Using HES in Critical Patients due to Fatality Risk
The Food and Drug Administration has decided to limit the use of Hydroxethyl Starch (HES), a blood volume expander, in critically ill patients or those in intensive care due increased risks of renal (kidney) injury and death.
The Medicine and Healthcare Products Regulatory Agency (MHRA) issued a press release saying it has decided to suspend the drug's use in the United Kingdom alltogether.
About Hydroxethyl (HES)
Hydroxethyl Starch (HES) is used to expand plasma in patients who have a diminished volume of circulating blood in there body. This often occurs after severe blood loss or an extreme loss of sodium and intravascular water (excessive sweating, diarrhea, or vomiting).
Limiting HES’s Use
- The FDA found that patients being treated with HES run a higher risk of renal (kidney) injury and mortality.
- The use of HES may result in excess bleeding during open heart surgery.
- The FDA warns that clinicians should stop using HES therapy at the first sign of renal injury.
- Clinicians should also stop treatment at the first sign of coagulopathy (blood coagulating either too slow or to fast).
- The MHRA has suspended use of HES drips as of June 27 stating its “benefits no longer outweigh the risks.”
Contact an Experienced Product Liability Attorney
Thomas J. Henry are leaders in the area of drug and product liability litigation. Our Defective Drug and Products Division have extensive knowledge and resources in order to represent our clients efficiently and aggressively. The Defective Drug and Products Division represent a multitude of people who are battling against manufacturers of medical devices and/ or defective pharmaceuticals.
If you or a loved one have been injured by or have developed serious side-effects from the use of defective medications or pharmaceuticals, contact Thomas J. Henry immediately. We represent clients/victims all over the country. We are available 24/7, nights and weekends.